Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission

被引：6

作者：

Miao, Xiaojuan ^{[1
]}

Shuai, Yanrong ^{[1
]}

Han, Ying ^{[1
]}

Zhang, Nan ^{[1
]}

Liu, Yilan ^{[1
]}

Yao, Hao ^{[1
]}

Wang, Xiao ^{[1
]}

He, Guangcui ^{[1
]}

Chen, Dan ^{[1
]}

Fan, Fangyi ^{[1
]}

Chang, Alex H. ^{[2
,3
]}

Su, Yi ^{[1
]}

Yi, Hai ^{[1
]}

机构：

[1] Sichuan Clin Res Ctr Hematol Dis, Branch Natl Clin Res Ctr Hematol Dis, Peoples Liberat Army Gen Hosp Western Theater Comm, Dept Hematol, Chengdu, Sichuan, Peoples R China

[2] Shanghai Yake Biotechnol Ltd, Shanghai, Peoples R China

[3] Fudan Univ, Engn Res Ctr Gene Technol, Sch Life Sci, Inst Genet,Minist Educ, Shanghai, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷

关键词：

relapsed/refractory; acute myeloid leukemia; C-type lectin-like molecule 1; donor-derived chimeric antigen receptor T cells; allogeneic hematopoietic stem cell transplantation;

D O I：

10.3389/fimmu.2024.1389227

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background Explore the efficacy and safety of donor-derived CLL-1 chimeric antigen receptor T-cell therapy (CAR-T) for relapsed/refractory acute myeloid leukemia (R/R AML) bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) after remission.Case presentation An adult R/R AML patient received an infusion of donor-derived CLL-1 CAR-T cells, and the conditioning regimen bridging to allo-HSCT was started immediately after remission on day 11 after CAR-T therapy upon transplantation. Then, routine post-HSCT monitoring of blood counts, bone marrow (BM) morphology, flow cytometry, graft-versus-host disease (GVHD) manifestations, and chimerism status were performed.Result After CAR-T therapy, cytokine release syndrome was grade 1. On day 11 after CAR-T therapy, the BM morphology reached complete remission (CR), and the conditioning regimen bridging to allo-HSCT started. Leukocyte engraftment, complete donor chimerism, and platelet engraftment were observed on days +18, +23, and +26 post-allo-HSCT, respectively. The BM morphology showed CR and flow cytometry turned negative on day +23. The patient is currently at 4 months post-allo-HSCT with BM morphology CR, negative flow cytometry, complete donor chimerism, and no extramedullary relapse/GVHD.Conclusion Donor-derived CLL-1 CAR-T is an effective and safe therapy for R/R AML, and immediate bridging to allo-HSCT after remission may better improve the long-term prognosis of R/R AML.

引用

页数：6

共 26 条

[1] C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia [J].